Research programme: glucose transporter type 1 inhibitors - IOmet Pharma

Drug Profile

Research programme: glucose transporter type 1 inhibitors - IOmet Pharma

Alternative Names: GLUT 1 inhibitors - IOmet Pharma; IOM1; IOM2; IOM3; IOM4

Latest Information Update: 04 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator IOmet Pharma
  • Class Small molecules
  • Mechanism of Action Glucose transporter type 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 16 Apr 2016 Pharmacodynamics data from a preclinical studies in Cancer presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
  • 11 Jan 2016 IOmet Pharma has been acquired by Merck & Co
  • 01 Mar 2014 Preclinical trials in Cancer in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top